Dr Badwe is Professor, Surgical Oncology & Director, Tata Memorial Centre, Mumbai, India. After qualifying in surgery from the KEM Hospital, Mumbai, he trained in cancer surgery at the Royal Marsden Hospital, London and at Guy’s Hospital, London. His original research carried out at Guy’s Hospital, London on ‘Timing of Surgery during the menstrual cycle for Operable Breast Cancer’ has changed the treatment planning in England and East Coast of USA. He is a reviewer for Lancet, British Journal of Cancer, Cancer, International Journal of Surgery, Annals of Oncology, Indian Journal of Surgery, and Indian Journal of Cancer and has several peer-reviewed publications to his credit. Among various other awards, he has received the Padma Shri National award conferred by the President of India for the contribution to the field of Medicine and the Lal Bahadur Shastri National award conferred by President of India for Excellence in Public Administration, Academics and Management.
Christopher Booth MD FRCPC is a Medical Oncologist and Health Services Researcher at Queen’s University in Kingston, Canada. He is an Associate Professor of Oncology and holds the Canada Research Chair in Population Cancer Care. Dr. Booth studied medicine at Queen’s University and did postgraduate training in Internal Medicine and Medical Oncology at the University of Toronto. Upon completing his clinical training he spent two years as a research fellow with the NCIC Clinical Trials Group. In his clinical practice he provides care to patients with gastrointestinal and genitourinary cancers. Dr. Booth has an active program in population-based cancer research. The focus of his research program is to evaluate the effectiveness of new therapies in the general population and the quality of care delivered to patients in routine clinical practice. Dr. Booth is the Co-Chair of the CHALLENGE study (NCIC CTG CO21), an international RCT evaluating whether physical activity can improve survival among patients with early stage colon cancer. As a junior investigator he was awarded an inaugural Cancer Care Ontario Chair in Health Services Research. Dr. Booth has published over 100 peer-reviewed manuscripts and served as research supervisor for >25 trainees. In 2016 Dr. Booth spent a sabbatical as a visiting scientist at the Regional Cancer Centre in Trivandrum, India to develop a collaborative program in health services research.
Marc Buyse holds a ScD in biostatistics from the Harvard School of Public Health (Boston, MA). He worked at the EORTC in Brussels and at the Dana Farber Cancer Institute in Boston. He is the founder of the International Drug Development Institute (IDDI) and of CluePoints, two biostatistical service organizations based in the US and Europe. His interests include clinical trial design, meta-analysis, validation of biomarkers and surrogate endpoints, statistical methods in oncology, statistical detection of errors and fraud, statistical monitoring of clinical trials, and medical data sharing (http://publicationslist.org/marc.buyse).
Dr Girish Chinnaswamy completed his medical school and post graduate training in paediatrics at Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) Pondicherry. He further underwent subspeciality training in paediatric and adolescent oncology at the Royal London and Newcastle Upon Tyne Hospitals in the United Kingdom. He subsequently pursued research in paediatric cancer pharmacology at the Northern Institute of Cancer Research, Newcastle University studying the pharmacokinetics and pharmacogenomics of anticancer drugs in Children. He has previously worked as a faculty in paediatric oncology at Christian Medical college hospital Vellore and is presently working as a consultant at Tata Memorial Hospital. His special interests are paediatric neuro-oncology and bone tumors in children.
Dr Gary M. Clark recently retired from Array BioPharma Inc. in Boulder, Colorado, USA, where he was Vice President of Biostatistics & Data Management. He has been actively involved in the development of targeted therapies for various cancers. His areas of expertise and interest include the identification and evaluation of prognostic and predictive biomarkers for breast cancer, lung cancer and other solid tumors, and the design and analysis of Phase I, II, III clinical trials of targeted therapies. Prior to joining Array BioPharma in 2008, he was Vice President of Biostatistics & Data Management at OSI Pharmaceuticals, Inc. in Boulder, Colorado, where he helped develop and was instrumental in the regulatory approval of a small molecule inhibitor of EGFR tyrosine kinase. Prior to joining OSI Pharmaceuticals in 2002, Dr. Clark served at Baylor College of Medicine in Houston, Texas (1999-2002) as Professor of Medicine and Associate Director of the Breast Center, Director of Tissue Resources, and Director of Informatics. His previous positions included service at the University of Texas Health Science Center at San Antonio, Texas (1980-1999) where he was Professor of Medicine in the Division of Medical Oncology and Director of the Biostatistics, Data Management & Data Processing Shared Resource of the San Antonio Cancer Institute. Dr. Clark has an extensive list of publications in the area of early drug development and has significantly contributed to the field of biomarkers in breast cancer and other solid tumours. He has been a member of numerous committees of the National Cancer Institute, AACR and ASCO, including several grant review and consensus development panels. He was co-director of the AACR/ASCO Workshop on Methods in Clinical Cancer Research in Vail, Colorado from 1996 to 2000, and co-director of the FECS/AACR/ASCO Workshop on Methods in Clinical Research in Flims, Switzerland, from 1999 to 2005. Dr. Clark has been an AACR representative and faculty member of the ACORD Workshop in Australia since 2008, and was a faculty member of the first CReDO Workshop in 2015.
Professor Chris Frampton is Professor, Biostatistics, Department of Medicine/Psychological Medicine, University of Otago, and Director of a statistical consultancy company based in Christchurch, New Zealand. In addition he is the statistical representative on New Zealand’s regulatory committees the Standing Committee on Therapeutic Trials, Medicines Adverse Reactions Committee, and Medicines Assessment Advisory Committee and on a number of national and international data safety monitoring committees for ongoing randomised controlled trials. Professor Frampton has a specific interest in the design, conduct and analysis of phase I, II and III randomised controlled trials. With over 25 years of experience in biostatistics consultancy as applied to a wide range of clinical disciplines he has co-authored over 600 peer reviewed publications.
Durga Gadgil is currently a consultant with the Tata Memorial Administrative and Research Council (TRAC). She is the chief coordinator for the two-year MSc in Clinical Research course conducted by the Tata Memorial Centre under the Homi Bhabha National Institute.
She has 31 years of experience in the pharmaceutical industry and retired in November 2015 as Area Head, Asia Pacific, Regional Medical Monitoring Organization, Pfizer. In this role, she was the line manager for medical monitors based in Australia, India, Singapore, Hong Kong, China, Korea, Taiwan and Philippines. The team was responsible for monitoring all global studies from Phase 2 to 4 for medical aspects, ensuring patient eligibility, protocol adherence, data integrity and quality, in compliance with local and global ethical principles.
Durga is a certified NABH assessor for NABH Accreditation Standards for Clinical Trials (Ethics Committee, Investigator, Clinical Trial Site)
During her career span of 30+ years, she has worked in many pharmaceutical companies, all MNCs and one India company. She has experience in all fields related to a medical doctor’s role in the industry, like medico-marketing support, regulatory activities, pharmacovigilance and safety reporting, clinical operations, medical monitoring, auditing and training.
Sarbani Ghosh-Laskar is a Professor and Consultant Radiation Oncologist in the Department of Radiation Oncology at the Tata Memorial Hospital, Mumbai, India. She has been a faculty at her alma mater for the last 15 years. She specializes in the treatment of Head & Neck Cancers and Esophageal Cancers with special interest in nasopharyngeal cancer, reradiation, Precision radiotherapy for head and neck cancers, brachytherapy for surface lesions and palliation in esophageal cancer. She has been a Principal Investigator of several investigator initiated trials and has also served as Co-investigator in several other investigator initiated and industry sponsored trials and has several publications on the same in various peer reviewed journals. Her areas of interest include outcomes studies dealing with the multidisciplinary management of head and neck and esophageal cancers, the OCAT, 3DCRT vs IMRT , palliative ILRT in advanced esophageal cancer, to name a few. She has also been serving as the Secretary of the Data and Monitoring Sub Committee of the Ethics Committee of the Institute for the last 6 years and is currently the Member Secretary of the IEC-II at the TMH. .
Allan Hackshaw is Professor of Epidemiology & Medical Statistics at University College London, and Deputy Director of the Cancer Research UK & UCL Cancer Trials Centre, one of the largest cancer trials units in the UK. He has >25 years’ experience in the design, conduct and interpretation of clinical trials (phase I-III), observational studies (cohort and case-control) and systematic reviews/meta-analyses: for prevention, screening or treatment. The main areas of research have been cancer; antenatal & cancer screening; and tobacco and health.
He has been a key co-investigator on successful grant funding applications (~£56 million in total), and published >150 articles in journals and book chapters,plus sole or first author of four textbooks. He leads modules on postgraduate courses (evidence-based medicine/clinical trials) at UCL, London School of Economics and Harvard. He has been a member of national and international scientific grant funding and data monitoring committees. Since 2012 he is named as one of the top 40 academic role models in biomedicine at UCL.
Dr. Hunsberger has worked at the National Institutes of Health for 25 years and has focused on clinical trials. She began her career in at the National Heart, Lung, and Blood Institute and then moved to the National Cancer Institute after 10 years. She worked at the National Cancer Institute for 12 years, specializing in breast cancer and pediatric clinical trial research. Dr. Hunsberger currently works at the National Allergy and Infectious disease institute where one of her main focuses is Influenza research.
Sadhana Kannan completed her postgraduation in Biostatistics from the Christian Medical College, Vellore and has been employed at the Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, since 2001. She has trained in the areas of management and analysis of clinical trial data, molecular epidemiological data, systematic review and meta-analysis. She has over 62 publications in national and international peer-reviewed journals
Ruth Langley is a medical oncologist with a particular interest in the design and management of clinical trials. Her training included time at the Joint Centre for Radiation Therapy, Boston USA studying for her PhD in radiation-induced apoptosis. She is based at the UK Medical Research Council Clinical Trials Unit in London where she jointly leads the Cancer Group. She has a particular interest in gastro-oesophageal malignancy and has co-ordinated a series of trials and associated translational studies, and has led the investigation of the use of transdermal oestrogen in the treatment of prostate cancer. A major focus of her recent work has been the development of an international trial to assess the effect of aspirin as an adjuvant agent in several common solid tumours.
She has an honorary clinical consultant post at the Brighton and Sussex University Hospital where she has a small clinical practice.
Dr Vikram Mathews is Professor and Head of the Department of Haematology, Christian Medical College, Vellore. After completing his undergraduate and post-graduate training in Medicine at Christian Medical College, Vellore, he further specialized in Clinical Haematology and completed his training in the same institution in 2001. Subsequently he did a three year postdoctoral fellowship in the Stem Cell Biology and Leukemia Unit at Washington University, St. Louis, MO, USA. Since 2004 he has been working in the department of Haematology at Christian Medical College, Vellore, India. His focus areas of research have been leukemia and stem cell transplantation. Based on his training, he is a physician-scientist and in addition to his clinical work, he runs his own laboratory which is mainly focused on research in acute myeloid leukemia and studying the role played by the microenvironment in mediating drug resistance. On the clinical side his major interest is in developing cost effective strategies to treat acute leukemia. There are significant context specific challenges in treating acute leukemia in India and he, along with his group, attempts to address such challenges. He has been involved in more than 100 peer reviewed publications and written 5 text book chapters.
Dr. Hari Menon, formerly Professor of Medical Oncology at the Tata Memorial Centre, is currently senior consultant, Medical Oncology at Cytecare Hospitals, Bangalore. His field of interest is Leukemia-lymphoma, which he continues to pursue. Having completed post graduation in Internal Medicine at the King Edward Memorial Hospital he proceeded to complete specialization in Medical Oncology at The All India Institute of Medical Sciences, New Delhi in 2004 following which he joined as Faculty at Tata Memorial Centre where he focused in the area of Leukemia and Lymphoma. Over the last eighteen years Dr. Menon has been actively involved with clinical research, clinical trials and has been a member of the Institutional review board for eight years until March 2016. After being exposed as a resident to multi-centric global studies he has persevered with his interest in clinical trial conduct, methodology, and designing of studies in the process gaining useful experience in the field of clinical trials and their methodologies. Besides being a busy clinician he has been a guide in studies involving junior faculty, post-graduate fellows and PhD students, helping them design and implement projects both in their clinical and laboratory fields. He has been a recipient of the ACORD clinical trial development workshop conducted by the Medical Oncology group of Australia and has been involved with the India Oxford (INDOX) clinical trial development program. He is a reviewer for both Indian and International Journals related to oncology and medicine and has been invited member on the advisory board for drug development involving multinational pharmaceutical industry. His niche area in the field of clinical trial is concept development, implementation and conduct of phase-I and phase-II studies.
Mahesh Parmar is a Professor of Medical Statistics and Epidemiology and Director of the MRC Clinical Trials Unit at UCL and the Institute of Clinical Trials and Methodology at University College London. He has been an Associate Director of the National Cancer Research Network since its inception in 2001, an organisation which has more than doubled the number of patients going into cancer studies in England. Max joined the MRC in 1987. He has more than 250 publications in peer reviewed journals, many of which have had direct impact on policy, clinical practice and improving outcomes for patients. The Unit he directs is at the forefront of resolving internationally important questions, particularly in infectious diseases and cancer, and also aims to deliver swifter and more effective translation of scientific research into patient benefits. It does this by carrying out challenging and innovative studies and by developing and implementing methodological advances in study design, conduct and analysis.
Professor Pramesh is a thoracic surgeon at the Tata Memorial Centre, the largest cancer centre in India. He is also a member of the Clinical Research Secretariat of the hospital and the coordinator for the National Cancer Grid, a large network of 84 cancer centres in India. In the latter role, he works extensively on enabling creation of uniform standards of cancer care, promoting equity in access to care and rational use of healthcare resources.
His primary clinical areas of interest include minimal invasive surgery and innovative treatment options in the management of esophageal and lung cancer. He is the Principal Investigator in several investigator-initiated research studies including randomised trials on cancer screening, surgical techniques, and neoadjuvant treatment of thoracic cancers. Professor Pramesh has strong interests in clinical trial designs, surgical trials, biostatistics and promoting collaborative research.
He is passionate about promoting training of early career physicians and surgeons in clinical research methods and conducts several formal and informal courses on clinical research methodology, biostatistics and scientific writing.
Professor Arnie Purushotham has been a Consultant Academic Surgeon for 22 years having worked in Glasgow, Cambridge and London. He is Professor of Breast Cancer at King’s College London and Consultant Surgeon at Guy’s and St Thomas NHS Foundation Trust in 2005. He is the Director of King’s Health Partners Comprehensive Cancer Centre and Senior Clinical Advisor to Cancer Research UK.
As a scientific researcher for the last 26 years, Professor Purushotham’s goal has been to drive high quality clinical and translational research that directly impacts on breast cancer patients. Key areas of research are patterns of metastatic spread, pathophysiology of lymphoedema, sentinel lymph node biopsy, novel optical intra-operative imaging, window of opportunity targeted therapy trials and cancer outcomes. His specific areas of expertise include study design, ethics and regulatory permissions, research governance, user involvement, window of opportunity studies and randomized controlled trials
Dr. Preetha Rajaraman is the South Asia Program Director for the NCI’s Center for Global Health, and is the representative of the U.S. National Cancer Institute (NCI) in India. She is responsible for strategic planning to help define the NCI’s portfolio and strategy in the South Asia region, and leads the development, oversight, and evaluation of regional programs for cancer research and training.
Dr. Rajaraman is a cancer epidemiologist, with an additional affiliation at NCI’s Division of Cancer Epidemiology and Genetics, where her research focuses on genetic susceptibility factors and their interaction with known or suspected environmental carcinogens, particularly with regard to the etiology of brain/central nervous system (CNS) tumors, and exposure to radiation from occupational and medical sources. Dr. Rajaraman has previously served on the Scientific Advisory Committees of the International Brain Tumor Epidemiology Consortium (BTEC), and the U.S. Childhood Cancer Survivor Study (CCSS). She is currently an expert member of Committee 1 (Biological Effects) of the International Commission of Radiation Protection and serves on the Advisory Board of the Mumbai South East Asia Regional hub for the International Agency for Research in Cancer (IARC).
Dr. Rajaraman received her Ph.D. in Epidemiology from the Johns Hopkins School of Public Health, with a concentration in cancer and molecular epidemiology. She has a Master’s of Science in Environmental Health from the University of Washington, Seattle, and an undergraduate degree in Biology (Phi Beta Kappa) from Reed College, Portland OR.
Priya Ranganathan works as a consultant anaesthesiologist at the Tata Memorial Centre, Mumbai. She completed her under-graduate and post-graduate training at the King Edward Memorial Hospital, Mumbai. She is a member of the Institutional Review Board at Tata Memorial Hospital and co-ordinates a post-graduate degree course in Clinical Research at TMC. She has organized several courses on biostatistics and clinical research methodology and is editor of the biostatistics section for the journal ‘Perspectives in Clinical Research’
Manju Sengar [MD (Medicine), DM (Medical Oncology)] is Professor, Adult hematolymphoid disease management group, Medical Oncology at the Tata Memorial Centre, Mumbai. Dr Sengar completed her training in Medical Oncology from All India Institute of Medical Sciences, New Delhi. She has done her post graduate diploma in clinical trials from London School of hygiene and tropical medicine (external programme). She is an ACORD alumnus. She is a recipient of American Society of Hematology visitor training program fellowship at Duke University, Durham. Her main areas of clinical research are non Hodgkin lymphomas in HIV/AIDS and adult acute lymphoblastic leukemia. She is the principal investigator for several investigator-initiated studies and has participated in industry sponsored multi-centre clinical trials.
Subir Sinha is Scientific Officer, Statistics in Tata Medical Centre, Kolkata. He received his B Stat and M Stat from Indian Statistical Institute (Kolkata), and Master’s from Carnegie Mellon University. He has worked at Novartis, Harvard School of Public Health and Alexion Pharmaceuticals. He has taught courses in Biostatistics in Boston School of Medicine and Harvard University. He has been an invited speaker at Indian Statistical Institute, Kolkata, Tata Memorial Centre, Mumbai and Indian Institute of Management, Ahmedabad. He has coauthored few publications in clinical oncology.
James Spicer is Consultant in Medical Oncology at Guy’s and St Thomas’ Hospitals, and Professor of Experimental Cancer Medicine at King’s College London. His clinical interests include the care of patients with thoracic malignancies, including lung cancer and mesothelioma, and clinical trials in these diseases. He set up and runs his hospital’s Cancer Early Phase Trials programme. He is joint Lead of the King’s Experimental Cancer Medicine Centre, funded by Cancer Research UK/National Institute for Health Research. His clinical interests include the care of patients with thoracic malignancies, including lung cancer and mesothelioma, and clinical trials in these diseases. His translational research focus is on novel immunotherapies and molecular diagnostics. He is a member of Cancer Research UK’s New Agents Committee and other national funding panels.
Martin Stockler is Professor of Oncology and Clinical Epidemiology at The University of Sydney, a consultant medical oncologist at the Concord Repatriation General Hospital and Chris O’Brien Lifehouse RPA, and Oncology Co-Director at the NHMRC Clinical Trials Centre. After internal medicine and medical oncology training in Sydney, Australia he spent 3 years in Toronto, Canada doing a clinical research fellowship at the Princess Margaret Hospital and a Masters in Clinical Epidemiology at the University of Toronto with Ian Tannock and Pamela Goodwin. His research focuses on using clinical trials to improve quality of life, survival, prognostication, and doctor-patient communication for those affected by cancer, particularly from genitourinary, thoracic, and gynaecologic primaries. His clinical focus is on genitourinary cancer. “The first protocol I wrote was for a randomised trial incorporating quality of life assessment in routine clinical practice, but this never went ahead. My first successful protocol was for a small (tiny), placebo-controlled, crossover trial of paracetamol (acetaminophen) for people with advanced cancer and troublesome pain despite a strong opioid regimen (J Clin Oncol 2004: 22; 3389).”
Dr. Tannock is Emeritus Professor of Medicine and Medical Biophysics at Princess Margaret Cancer Centre and University of Toronto. He obtained his PhD in London, England and his MD at University of Pennsylvania, Philadelphia, USA. His clinical research investigates methods related to cancer clinical trials, and he chaired trials for men with metastatic prostate cancer that led to licensing of previous (mitoxantrone) and current (docetaxel) standard chemotherapy.
His laboratory research evaluates effects of the tumour microenvironment on outcome of cancer therapy. He is an editor of the Basic Science of Oncology textbook, now in its 5th edition that is used by trainees in all branches of oncology. Dr. Tannock was a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) from 2001-2004. He received the alumnus award from M.D. Anderson Hospital, Houston, USA (1989), the Warwick Prize from the National Cancer Institute of Canada (2003), an honorary degree (DSc) from London University, UK (2009), and the European Society of Medical Oncology (ESMO) award (2012), the first non-European to receive this award. He chairs the scientific audit committee of the European Organisation for Research and Treatment of Cancer (EORTC) and is a member of the EORTC Board.
Dr. Tannock was appointed a Member of the Order of Canada in December 2013.
Dr Tejpar is a trained gastro enterologist and oncologist with a PhD in molecular biology. She works as a part-time clinician and part-time researcher (Senior Clinical Investigator of the Fund for Scientific Research- Flanders), with a focus on basic and translational research in colorectal cancer. Her current positions are as Associate Professor of Medicine – Head of the Laboratory of Molecular Digestive Oncology, KU Leuven and Adjunct Clinical Head – Dept of Gastroenterology, Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven. She is Chair of the Translational Research Committee, European Organisation for the Research and Treatment of Cancer (EORTC) and board member since 2012. From 2014 onwards, she has been the founder of the molecular screening platforms (SPECTA) at EORTC. She is Chair of the NCI-AACR-EORTC-EMA run course on biomarker discovery and validation. Her areas of expertise in translational research consist of a large scale molecular interrogation of human colorectal cancer samples (polyps, tumors and mets) for mapping of subgroup, pathway alterations and oncogenic events and testing of these features in clinical trial series for prognostic and predictive marker discovery.
Dr.Shivakumar Thiagarajan graduated from KIMS, Bangalore. After which he did his post-graduation in Otolaryngology from the Indian AirForce Hospital, Bangalore. He further underwent sub-speciality training in Head and Neck Surgical Oncology from Kidwai Memorial Institute of Oncology, Bangalore and Tata Memorial centre, Mumbai. He was actively involved in both clinical and translational research during his training. He has worked as a faculty in both Otolaryngology and Head and Neck surgical oncology, during which he has been part of various research projects. He is presently working as a faculty in the department of Head and Neck surgical oncology, Tata Memorial Centre, Mumbai, India. His primary clinical interest is in the management of oral, thyroid and skull base malignancies.